Akebia Therapeutics Inc. (AKBA) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) Comparison side by side

This is therefore a comparing of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Akebia Therapeutics Inc. (NASDAQ:AKBA) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akebia Therapeutics Inc. 6 2.17 N/A -2.40 0.00
ImmunoCellular Therapeutics Ltd. N/A 0.00 N/A -0.48 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Akebia Therapeutics Inc. and ImmunoCellular Therapeutics Ltd.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Akebia Therapeutics Inc. 0.00% -23.8% -12.1%
ImmunoCellular Therapeutics Ltd. 0.00% -321.9% -158.6%

Volatility and Risk

Akebia Therapeutics Inc.’s current beta is 1.31 and it happens to be 31.00% more volatile than Standard & Poor’s 500. From a competition point of view, ImmunoCellular Therapeutics Ltd. has a -0.31 beta which is 131.00% less volatile compared to Standard & Poor’s 500.

Liquidity

1.8 and 1.3 are the respective Current Ratio and a Quick Ratio of Akebia Therapeutics Inc. Its rival ImmunoCellular Therapeutics Ltd.’s Current and Quick Ratios are 9.5 and 9.5 respectively. ImmunoCellular Therapeutics Ltd. has a better chance of clearing its pay short and long-term debts than Akebia Therapeutics Inc.

Analyst Recommendations

The Recommendations and Ratings for Akebia Therapeutics Inc. and ImmunoCellular Therapeutics Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Akebia Therapeutics Inc. 0 1 2 2.67
ImmunoCellular Therapeutics Ltd. 0 0 0 0.00

Akebia Therapeutics Inc. has a consensus price target of $15.67, and a 263.57% upside potential.

Insider and Institutional Ownership

The shares of both Akebia Therapeutics Inc. and ImmunoCellular Therapeutics Ltd. are owned by institutional investors at 69.7% and 4.3% respectively. About 1.1% of Akebia Therapeutics Inc.’s share are owned by insiders. Comparatively, 0.3% are ImmunoCellular Therapeutics Ltd.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akebia Therapeutics Inc. -1.7% -17.52% -10.23% -35.38% -44.49% 4.7%
ImmunoCellular Therapeutics Ltd. -18.15% -21.62% -21.77% -36.31% -92.54% 19.88%

For the past year Akebia Therapeutics Inc.’s stock price has smaller growth than ImmunoCellular Therapeutics Ltd.

Summary

On 5 of the 8 factors Akebia Therapeutics Inc. beats ImmunoCellular Therapeutics Ltd.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.